Sol-Gel Technologies (SLGL) Retained Earnings (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Retained Earnings of -$240.7 million for Q1 2026, little changed year-over-year from -$241.8 million in Q1 2025, and down 1.57% quarter-over-quarter from -$237.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Retained Earnings (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Retained Earnings data on file, last reported at -$240.7 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$240.7 million, changed 0.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$240.7 million (changed 0.44% YoY), and the FY2025 annual result was -$237.0 million, down 2.65% from the prior year.
- Retained Earnings declined to -$240.7 million in Q1 2026 per SLGL's latest filing, from -$237.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$183.7 million in Q1 2022 and troughed at -$240.7 million in Q1 2026.
- A 5-year average of -$216.7 million and a median of -$224.7 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings advanced 4.96% in 2022, then declined 15.05% in 2023.
- A 5-year view of Retained Earnings shows it stood at -$193.1 million in 2022, then slipped by 14.11% to -$220.3 million in 2023, then dropped by 4.8% to -$230.9 million in 2024, then retreated by 2.65% to -$237.0 million in 2025, then dropped by 1.57% to -$240.7 million in 2026.
- Business Quant data shows SLGL's Retained Earnings at -$240.7 million in Q1 2026, -$237.0 million in Q4 2025, and -$234.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | -240.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -240.74 Mn |
| Dec 31, 2025 | -237.01 Mn |
| Sep 30, 2025 | -234.02 Mn |
| Jun 30, 2025 | -228.08 Mn |
| Mar 31, 2025 | -239.69 Mn |
| Dec 31, 2024 | -230.88 Mn |
| Sep 30, 2024 | -225.04 Mn |
| Jun 30, 2024 | -224.67 Mn |
| Mar 31, 2024 | -226.65 Mn |
| Dec 31, 2023 | -220.30 Mn |
| Sep 30, 2023 | -215.47 Mn |
| Jun 30, 2023 | -209.76 Mn |
| Mar 31, 2023 | -203.33 Mn |
| Dec 31, 2022 | -193.07 Mn |
| Sep 30, 2022 | -187.28 Mn |
| Jun 30, 2022 | -183.87 Mn |
| Mar 31, 2022 | -183.74 Mn |
| Dec 31, 2021 | -178.14 Mn |
| Sep 30, 2021 | -192.17 Mn |
| Jun 30, 2021 | -193.46 Mn |